Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia
Antibiotics · 01.01.2026 · 15 (1) · 34
DOI: 10.3390/antibiotics15010034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 01.01.2026. Verfasst von Tim Rahmel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Knappschaft Kliniken University Hospital Bochum, Ruhr-University Bochum, 4489…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Pneumonieprophylaxe
Abstract (Originalsprache)
Ventilator-associated pneumonia (VAP) remains the most frequent ICU-acquired infection and a major driver of antimicrobial exposure. Historically, clinicians treated patients for 10–14 days or longer, particularly when multidrug-resistant organisms were suspected. Current evidence from randomized trials and meta-analyses now supports shorter-course therapy (~7 days) for most immunocompetent patients with VAP who demonstrate clinical improvement. Mortality and treatment failure are not increased when compared with longer regimes. The REGARD-VAP trial demonstrated the non-inferiority of individualized ≤7-day therapy compared with conventional longer courses. This remained true even in cohorts rich in non-fermenting Gram-negative bacilli (NF-GNB) and carbapenem-resistant organisms while markedly reducing antibiotic-related toxicity. North American and European guidelines recommend 7–8 days as the default duration, with individualized extension for slow clinical response, bacteremia, uncontrolled foci, or profound immunosuppression. Additionally, biomarker-guided discontinuation, particularly serial procalcitonin (PCT), may reduce antibiotic days when used to enrich clinical assessment. This narrative review synthesizes guideline recommendations, trial evidence, biomarker-guided stewardship, and pathogen- and patient-specific scenarios to provide a practical framework for intensivists: treat until infection is controlled and the patient is improving, usually about 1 week, and extend therapy only with clear justification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Knappschaft Kliniken University Hospital Bochum, Ruhr-University Bochum, 44892 Bochum, Germany.
- Division of Clinical Infectious Diseases and Internal Critical Care, Department of Internal Medicine, Knappschaft Kliniken University Hospital Bochum, Ruhr-University Bochum, 44892 Bochum, Germany.
- Department of Emergency Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
- Faculty of Health Sciences, Poznań University of Medical Sciences, 60-806 Poznań, Poland.
- Critical Care Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
- UQ Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane 4072, Australia.
ORCID-Profile: Tim Rahmel, Maria Panagiota Almyroudi, Barbara Tamowicz, Antonios Katsounas
Zitieren
APA
Rahmel, T., Traut, I., Bergmann, L., Almyroudi, M. P., Tamowicz, B., Varma, P., Koulenti, D., & Katsounas, A. (2026). Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia. Antibiotics, 15(1), 34. https://doi.org/10.3390/antibiotics15010034
Vancouver
Rahmel T, Traut I, Bergmann L, Almyroudi MP, Tamowicz B, Varma P, et al. Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia. Antibiotics. 2026;15(1):34. doi:10.3390/antibiotics15010034
BibTeX
@article{Rahmel2026,
author = {Rahmel, Tim and Traut, Isabella and Bergmann, Lars and Almyroudi, Maria Panagiota and Tamowicz, Barbara and Varma, Priyam and Koulenti, Despoina and Katsounas, Antonios},
title = {Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {1},
pages = {34},
doi = {10.3390/antibiotics15010034}
}
EUVIMED